University of Birmingham has spun out Viatem to develop a treatment for rheumatoid arthritis.
University of Birmingham established Viatem, a UK-based developer of a treatment for rheumatoid arthritis, yesterday with an undisclosed amount of capital.
The funding was provided by University of Birmingham’s Enterprising Birmingham Fund, Innovate UK and West Midlands Academic Health Science Network.
Viatem will develop the peptide inhibitor of trans-endothelial migration (Pepitem), which plays a part in bringing immune cells into inflamed tissues.
Synthetic Pepitem has been shown to prevent or delay the onset of rheumatoid arthritis in animal models and…
